FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non–Small Cell Lung Cancer
Michael I. Barbato(United States Food and Drug Administration), Nicole Drezner(Center for Drug Evaluation and Research), Jeanne Fourie Zirkelbach(United States Food and Drug Administration), Diana Bradford(Center for Drug Evaluation and Research), Lili Pan(United States Food and Drug Administration), Anup Amatya(Center for Drug Evaluation and Research), Jianghong Fan(United States Food and Drug Administration), Sarah E. Dorff(United States Food and Drug Administration), Barbara Scepura(Center for Drug Evaluation and Research), Harpreet Singh(United States Food and Drug Administration), Peter Schotland(United States Food and Drug Administration), Stephanie Aungst(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Manuela Grimstein(United States Food and Drug Administration), Claudia P. Miller(Center for Drug Evaluation and Research), Pallavi S. Mishra‐Kalyani(Center for Drug Evaluation and Research), Idara Ojofeitimi(United States Food and Drug Administration), Youwei Bi(Center for Drug Evaluation and Research), Opeyemi Udoka(United States Food and Drug Administration), Yi Ren(Center for Drug Evaluation and Research), Yangbing Li(Center for Drug Evaluation and Research), John K. Leighton, Nam Atiqur Rahman(United States Food and Drug Administration)
Cited by 13
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k